Novo Nordisk (NVO) has reported positive topline results from the PIONEER TEENS, the first clinical trial to test an oral GLP-1 receptor agonist in children and adolescents aged 10-17 years with type 2 diabetes.
The company said the therapy delivered a statistically significant and superior reduction in blood sugar versus placebo at 26 weeks, highlighting its potential to become the first oral GLP-1 option for this age group.
Type 2 diabetes in children is a growing global concern, with rising rates linked to obesity and limited treatment options. Current guidelines rely mainly on metformin and insulin, but many young patients struggle to maintain adequate blood sugar control, underscoring the need for new therapies.
The Phase 3a PIONEER TEENS trial enrolled 132 participants and evaluated oral Semaglutide at once-daily doses of 3 mg, 7 mg, or 14 mg. The primary endpoint measured change in HbA1c, a key marker of long-term glucose control. Novo Nordisk reported an average 0.83% greater reduction in HbA1c versus placebo at week 26, with a safety profile consistent with previous Semaglutide studies in adults.
Oral Semaglutide is already approved for adults with type 2 diabetes under the brand name Rybelsus, and is expected to launch in the U.S. as the Ozempic pill later this year. Based on the new data, Novo Nordisk plans to file for a label expansion in the U.S. and EU in the second half of 2026.
If approved, the therapy could offer a new, convenient treatment option for young people who require better glycemic control than current standard therapies can provide.
NVO has traded between $35.12 and $81.44 over the past year. The stock closed Wednesday's trading at $39.15, down 0.68%. In pre-market trading, the stock is at $39.26, up 0.28%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.